ATE55908T1 - Grenzflaechenaktives mittel und dieses enthaltende arzneimittel zur verwendung bei der behandlung des atemnotsyndroms. - Google Patents

Grenzflaechenaktives mittel und dieses enthaltende arzneimittel zur verwendung bei der behandlung des atemnotsyndroms.

Info

Publication number
ATE55908T1
ATE55908T1 AT84301513T AT84301513T ATE55908T1 AT E55908 T1 ATE55908 T1 AT E55908T1 AT 84301513 T AT84301513 T AT 84301513T AT 84301513 T AT84301513 T AT 84301513T AT E55908 T1 ATE55908 T1 AT E55908T1
Authority
AT
Austria
Prior art keywords
respiratory distress
distress syndrome
treatment
active agent
surfactant
Prior art date
Application number
AT84301513T
Other languages
English (en)
Inventor
Takei Tsunetomo
Kanazawa Yosaku
Masuda Kazuo
Tanaka Yuji
Original Assignee
Tokyo Tanabe Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12518415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE55908(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tokyo Tanabe Co filed Critical Tokyo Tanabe Co
Application granted granted Critical
Publication of ATE55908T1 publication Critical patent/ATE55908T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0082—Lung surfactant, artificial mucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
AT84301513T 1983-03-10 1984-03-07 Grenzflaechenaktives mittel und dieses enthaltende arzneimittel zur verwendung bei der behandlung des atemnotsyndroms. ATE55908T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP58038189A JPS59164724A (ja) 1983-03-10 1983-03-10 サ−フアクタント及びそれを含有する呼吸窮迫症候群治療剤
EP84301513A EP0119056B1 (de) 1983-03-10 1984-03-07 Grenzflächenaktives Mittel und dieses enthaltende Arzneimittel zur Verwendung bei der Behandlung des Atemnotsyndroms

Publications (1)

Publication Number Publication Date
ATE55908T1 true ATE55908T1 (de) 1990-09-15

Family

ID=12518415

Family Applications (1)

Application Number Title Priority Date Filing Date
AT84301513T ATE55908T1 (de) 1983-03-10 1984-03-07 Grenzflaechenaktives mittel und dieses enthaltende arzneimittel zur verwendung bei der behandlung des atemnotsyndroms.

Country Status (10)

Country Link
US (1) US4603124A (de)
EP (1) EP0119056B1 (de)
JP (1) JPS59164724A (de)
AT (1) ATE55908T1 (de)
AU (1) AU562676B2 (de)
CA (1) CA1208129A (de)
DE (1) DE3483055D1 (de)
GR (1) GR81930B (de)
IE (1) IE57006B1 (de)
MX (1) MX9203493A (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5430020A (en) * 1984-12-11 1995-07-04 Scios Nova Inc. Recombinant alveolar surfactant protein
US5110806A (en) * 1985-06-26 1992-05-05 The Regents Of The University Of California Lung surfactant compositions
DE3528934A1 (de) * 1985-08-13 1987-02-26 Feldmuehle Ag Gleitelement aus keramischem werkstoff
WO1987002037A1 (en) * 1985-09-26 1987-04-09 Genetics Institute, Inc. Pulmonary surfactant proteins
US5256569A (en) * 1986-01-21 1993-10-26 Chisso Corporation Transesterification process for otereoselection of enantiomers of secondary alcohols using pseudomonas lipase with no added solvent
IT1203873B (it) * 1987-04-08 1989-02-23 Chiesi Farma Spa Composizioni farmaceutiche che lo surfattante polmonare naturale, contengono. metodo di preparazione e
US4861756A (en) * 1988-03-08 1989-08-29 Merrell Dow Pharmaceuticals Inc. Synthetic pulmonary surfactant
DE3921954A1 (de) * 1989-07-04 1991-01-17 Thomae Gmbh Dr K Niedrig-viskose, hochkonzentrierte surfactant-suspension
US5174988A (en) * 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
US5207220A (en) * 1989-12-12 1993-05-04 Burroughs Wellcome Co. Method for administering pharmaceuticals, including liquid surfactant, to the lungs
FR2658418B1 (fr) * 1990-02-20 1994-09-02 Synthelabo Compositions pharmaceutiques a base de phospholipides.
DE69131163T2 (de) * 1990-05-18 1999-12-23 Tokyo Tanabe Co Asthma heilmittel
US5614216A (en) * 1990-10-17 1997-03-25 The Liposome Company, Inc. Synthetic lung surfactant
JP3961029B2 (ja) * 1992-06-24 2007-08-15 博 木戸 インフルエンザウィルス感染防止剤
DE4418936A1 (de) * 1994-05-31 1996-02-08 Byk Gulden Lomberg Chem Fab Polypeptid
BR9506114A (pt) * 1994-12-29 1997-12-23 Ctro Nac Sanidad Agropecuaria Tensoativo pulmonar de origem suína e processo para a sua obtenção
US6129934A (en) * 1995-06-07 2000-10-10 Ony, Inc. Modification of animal lung surfactant for treating respiratory disease due to lung surfactant deficiency or dysfunction
US6315983B1 (en) 1996-01-24 2001-11-13 Byk Gulden Lomberg Chemische Fabrik Gmbh Process for the production of powdered pulmonary surfactant preparations
US6172203B1 (en) * 1996-02-07 2001-01-09 Alfredo Adolfo Hager Method for extracting and purifying pulmonary surfactant
WO1997035882A1 (en) * 1996-03-27 1997-10-02 Ortho Pharmaceutical Corporation Lyophilized pulmonary surfactant peptide compositions
US5667948A (en) * 1996-04-16 1997-09-16 Eastman Kodak Company Processing silver halide films with an aqueous phospholipid rinse solution
AU1250999A (en) 1997-12-24 1999-07-19 Britannia Pharmaceuticals Limited Use of surface active agent for the manufacture of a medicament for treatment ofdisorders of the middle ear
EP1216052A1 (de) 1999-09-16 2002-06-26 Byk Gulden Lomberg Chemische Fabrik GmbH Kombination eines c1-inh und eines lungensurfactant zur behandlung von respirationstörungen
DE10018022A1 (de) * 2000-04-12 2001-10-31 Byk Gulden Lomberg Chem Fab Neue Verwendung von Lungensurfactant zur Prophylaxe oder Frühbehandlung von akuten Lungenerkrankungen
GB0026239D0 (en) * 2000-10-26 2000-12-13 Britannia Pharmaceuticals Ltd Surface active lipids in treatment of wet lung
AU2002338882B2 (en) 2001-10-11 2008-04-03 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Novel use of pulmonary surfactant
EP1481665A1 (de) * 2003-05-30 2004-12-01 CHIESI FARMACEUTICI S.p.A. Neue Lipidmischungen für synthetische Tenside
WO2006013183A1 (en) 2004-08-06 2006-02-09 Altana Pharma Ag Composition comprising a pulmonary surfactant and a tnf-derived peptide
US7582312B2 (en) * 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
US8337815B2 (en) * 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
US7951781B2 (en) 2006-11-02 2011-05-31 University Of Iowa Research Foundation Methods and compositions related to PLUNC surfactant polypeptides
US9289388B2 (en) 2008-12-10 2016-03-22 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of medicaments to the lungs
EP2608769B1 (de) 2010-08-23 2019-11-06 Fraunhofer Gesellschaft zur Förderung der Angewand Befeuchtete partikel mit einem wirkstoff
HUE026363T2 (en) * 2012-03-28 2016-06-28 Discovery Lab Inc Lyophilization of pulmonary synthetic liposomal surfactant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE388023C (de) * 1922-02-14 1924-01-07 Chem Fab Verfahren zur Herstellung von waesserigen Lezithinemulsionen
FR2343481A1 (fr) * 1976-03-11 1977-10-07 Gerlich Norbert Composition destinee a empecher les lesions des membranes biologiques et a regenerer ces membranes une fois qu'elles ont ete endommagees
DE2900300A1 (de) * 1979-01-05 1980-07-17 Lebrecht Von Dr Klitzing Verfahren einer prophylaxe zur vermeidung des atemnotsyndroms bei fruehgeborenen und bei der schocklunge
JPS55160721A (en) * 1979-06-02 1980-12-13 Tokyo Tanabe Co Ltd Pulmonary surfactant ta-546, its preparation, and remedy for pulmonary hyaline membrane syndrome comprising it as active constituent
US4312860A (en) * 1980-10-24 1982-01-26 Regents Of The University Of California Lung surfactant compositions
JPS5845299A (ja) * 1981-09-10 1983-03-16 東京田辺製薬株式会社 新規な表面活性物質、その製造法及びそれを含有する呼吸窮迫疾候群治療剤

Also Published As

Publication number Publication date
IE57006B1 (en) 1992-03-11
DE3483055D1 (de) 1990-10-04
AU562676B2 (en) 1987-06-18
EP0119056A2 (de) 1984-09-19
US4603124A (en) 1986-07-29
JPH0378371B2 (de) 1991-12-13
AU2512584A (en) 1984-09-13
IE840553L (en) 1984-09-10
EP0119056A3 (en) 1986-06-25
EP0119056B1 (de) 1990-08-29
JPS59164724A (ja) 1984-09-17
CA1208129A (en) 1986-07-22
GR81930B (de) 1984-12-12
MX9203493A (es) 1992-08-01

Similar Documents

Publication Publication Date Title
ATE55908T1 (de) Grenzflaechenaktives mittel und dieses enthaltende arzneimittel zur verwendung bei der behandlung des atemnotsyndroms.
Heppleston et al. Changes in the composition of lung lipids and the “turnover” of dipalmitoyl lecithin in experimental alveolar lipo-proteinosis induced by inhaled quartz
JPS5799524A (en) Mammal lung surface active drug composition
ATE84799T1 (de) Biologisch wirksames lipoprotein und seine verwendung.
ATE113834T1 (de) Zusammensetzung zur behandlung der schizophrenie.
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
NO912943D0 (no) Anvendelse av nervonsyre og langkjedete fettsyrer for behandling av demyelineringsforstyrrelser.
DE3855113T2 (de) Verwendung von Buspiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung der Alkoholsucht
JPS5513275A (en) Prodrug of non-steroid anti-inflammatory drug having improved absorption and anti-inflammatory drug composition comprising it
ATE144142T1 (de) Verwendung von thiazolidin-4-carboxylatderivaten zur behandlung von lungenerkrankungen
ATE35415T1 (de) Pharmazeutische zusammensetzungen und verfahren fuer die herstellung von zusammensetzungen mit gehalt an phosphatidylserine zur behandlung von stoerungen des centralen nervensystems ohne wirkungen auf die blutkoagulation.
DE69122364T2 (de) Verwendung von (S)-Isofluran und (S)-Desfluran zur Anästhesie sowie entsprechende Arzneimittelzubereitungen
JPS5592312A (en) Suppository containing bronchodilating compound
ATE227304T1 (de) Tetraetherlipide und diese enthaltende liposomen sowie deren verwendung
JPS56127308A (en) Blood-coagulation factor 8 pharmaceutical
DE69131553T2 (de) Arzneimittel enthaltend Mischungen von höheren primären aliphatischen Alkoholen zur Behandlung von Hypercholesterolämie und Hyperlipoproteinämie Typ II und zur Stimulation des sexuellen Verhaltens bei Tieren und Menschen
ATE3552T1 (de) Verfahren zur herstellung von phosphono-hydroxy- essigsaeure und salzen derselben sowie diese enthaltende autivirale mittel.
DE69132211T2 (de) Synthetische oberflächenaktive agentien auf der lunge
DE69501183T2 (de) Feste orale pharmazeutische Zubereitung mit Gemfibrozil als aktiver Inhaltsstoff und Verfahren zur Herstellung
ATE119908T1 (de) 2-formylbenzylphosphonsäure-derivate, deren herstellung und ihre verwendung zur behandlung von durch viren verursachte krankheiten.
JPS5626819A (en) Preventive for hypoimmunity
NO894083L (no) Farmasoeytiske blandinger for behandling av adrenoleukodystrophy.
NO913685D0 (no) Fremgangsmaate for fremstilling av kalsiumopptaksinhibitorer.
ATE139703T1 (de) Aureobasidin enthaltendes arzneimittel
ES2092969A1 (es) Surfactante pulmonar natural de origen porcino.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
RZN Patent revoked